spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

YHEC announces the promotions of Michelle Jenks and Rachael McCool to the role Project Director

YHEC

Michelle Jenks and Rachael McCool announced as YHEC Project Directors

YHEC is pleased to announce the promotions of Michelle Jenks from the Economic Modelling team and Rachael McCool from the Systematic Reviewing team to the role Project Director.

Michelle has a Master’s degree (MSc) in health economics from the University of York and has conducted economic evaluations and systematic reviews for both public and private sector clients. Michelle is the lead modeller in YHEC’s role as an External Assessment Centre for NICE and has also led on a range of economic evaluations conducted for clients within industry, such as cost-utility models and budget impact models. She often leads the development of early economic analyses to inform clinical trial design and pricing strategy.

Rachael has a BSc (Hons) in psychology from the University of York and has developed extensive experience in systematic reviewing and mixed treatment comparisons during her time at YHEC. Rachael has led systematic reviews requiring both quantitative and qualitative analyses and has worked on several reviews to support reimbursement submissions to NICE and other HTA bodies. She has also contributed to critiques of evidence submitted to NICE’s medical technologies evaluation program. In her previous role, Rachael worked on developing and validating patient reported outcome measures using qualitative methods as well as critiquing existing measures against regulatory agency standards. She has worked with clients to assist them in their choice of PRO endpoint and outcome assessment in trials.
phone +44 (0)1904 323620
email andria.hanbury@york.ac.uk
web www.yhec.co.uk/
email Address: YHEC, Enterprise House, Innovation Way, University of York, York, YO10 5NQ, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Porton Biopharma opens new facility to make more of its childhood cancer cure

In a ribbon cutting ceremony, John Glen MP for Salisbury and South Wiltshire today (27th April 2018) officially opened Porton Biopharma Limited’s (PBL) new fermentation facility which will be used to manufacture the company’s life-saving leukaemia drug Erwinase®.   
More info >>


White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

Industry Events

BioPharm America 2018

5-6 September 2018, Hynes Convention Center

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement